Summary:
In patients with heart failure with preserved ejection fraction (HFpEF), obesity, and with or without type 2 diabetes, tirzepatide (up to 15 mg weekly) significantly reduced the risk of cardiovascular death or worsening heart failure and improved clinical status and quality of life compared to placebo, though it was associated with slightly less weight loss in patients with type 2 diabetes.
| PICO | Description |
|---|---|
| Population | Adults with heart failure with preserved ejection fraction (HFpEF) and a body mass index ≥30 kg/m², both with and without type 2 diabetes. |
| Intervention | Tirzepatide administered subcutaneously at doses up to 15 mg once weekly for a median duration of 104 weeks. |
| Comparison | Placebo group receiving standard care, stratified by presence or absence of type 2 diabetes at baseline. |
| Outcome | Tirzepatide reduced the rate of cardiovascular death or worsening heart failure events (HR: 0.62; P = 0.026), and improved Kansas City Cardiomyopathy Questionnaire scores, 6-minute walk distance, NYHA class, and quality of life. Benefits were consistent in patients with and without diabetes. Weight loss was slightly attenuated in those with diabetes but reductions in visceral adiposity and left ventricular mass were similar across groups. |
Source: Milton Packer, et al. “Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.” Read article here.
